NEW YORK, Aug. 12, 2013 /PRNewswire/ -- Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of the securities of Vical Incorporated ("Vical" or the "Company") (NasdaqGS: VICL). The investigation focuses on whether the Company and its executives violated federal securities laws.
On August 12, 2013, shares of Vical fell $2.05 or 57% to trade $1.53 during intraday trading after the company announced it would stop development its drug, Allovectin, after a late-stage trial failed to show that the treatment was significantly better than chemotherapy. According to one analyst who said shareholders would have been better served had the company analyzed the main and secondary goals separately and ended the trial 12 to 18 months ago, when data showing that the tumors did not shrink was first available.
If you are aware of any facts relating to this investigation, or purchased shares of Vical you can assist this investigation by contacting either Peretz Bronstein or his Investor Relations Coordinator Eitan Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email firstname.lastname@example.org. Those who inquire by e-mail are encouraged to include their mailing address and telephone number.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.Contact:Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Eitan Kimelman 212-697-6484 email@example.com SOURCE Bronstein, Gewirtz & Grossman, LLC